Boston — Celea Therapeutics said it will present the design of its Phase 3 SURPASS-IPF trial of deupirfenidone and a separate analysis of statistical methods used to evaluate idiopathic pulmonary fibrosis clinical trials at the IPF Summit 2026.
The clinical-stage biopharmaceutical company is developing deupirfenidone, also known as LYT-100, as an investigational treatment for idiopathic pulmonary fibrosis, or IPF.
The SURPASS-IPF study is evaluating whether deupirfenidone 825 mg three times daily is superior to pirfenidone 801 mg three times daily. Celea said the study is the first industry-sponsored Phase 3 head-to-head trial comparing an investigational drug with an approved antifibrotic in patients with IPF.
A second poster presentation will focus on statistical considerations for evaluating forced vital capacity, or FVC, a commonly used measure of disease progression and a primary endpoint in many IPF clinical trials, including SURPASS-IPF. The analysis will examine how different statistical approaches can affect interpretations of efficacy.
“Building on positive Phase 2b results, SURPASS-IPF takes an important next step by directly comparing deupirfenidone to pirfenidone in IPF,” said Sven Dethlefs, Ph.D., Chief Executive Officer of Celea.
“We are applying carefully considered statistical methods to rigorously evaluate whether deupirfenidone is superior to a current standard of care, with the goal of generating clear, robust evidence that can help advance treatment for people living with IPF,” Dethlefs added.
Toby Maher, M.D., Ph.D., Director of Interstitial Lung Disease at the Keck School of Medicine of the University of Southern California, will present both posters at the IPF Summit in Boston on September 30.
One presentation will detail the design of SURPASS-IPF, while the second will examine statistical considerations in the Phase 3 comparison of deupirfenidone and pirfenidone.
The IPF Summit 2026 is being held in Boston from September 29 through October 1.
